Related Experiment Videos

Glucocorticoid-induced osteoporosis

J D Ringe1

  • 1Geriatrische Klinik, Städtisches Krankehaus, Akademisches Lehrkrankenhaus, Universität Köln, Leverkusen, Federal Repubic of Germany.

Insights

Glucocorticoid-induced osteoporosis (GC-OP) is a significant secondary osteoporosis. Salmon calcitonin (sCT) treatment improved bone mineral content and reduced pain in patients with GC-OP.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid-induced osteoporosis (GC-OP) is a major secondary osteoporosis.
  • Key mechanisms include inhibited osteoblast formation, stimulated osteoclast resorption, and impaired calcium absorption.
  • Factors like dosage, duration, age, and sex influence GC-OP development.

Purpose of the Study:

  • To investigate the efficacy of salmon calcitonin (sCT) in treating manifest GC-OP.
  • To evaluate the impact of sCT on bone mineral content and pain in patients with chronic obstructive lung disease on prednisone therapy.

Main Methods:

  • A randomized controlled trial involving 36 patients with GC-OP.
  • 18 patients received 100 U sCT subcutaneously every second day.
  • 18 patients served as untreated controls.

Main Results:

  • The sCT group showed a significant reduction in pain.
  • Bone mineral content in the distal radius increased by 2.7% in the sCT group over six months.
  • The control group experienced a 3.5% decrease in bone mineral content (p < 0.001).

Conclusions:

  • Salmon calcitonin (sCT) is effective in improving bone mineral density and alleviating pain in patients with GC-OP.
  • sCT offers a potential therapeutic strategy to counteract the detrimental effects of long-term glucocorticoid use on bone health.

Related Concept Videos